Evidence map›Paper›PMID 40149304›Full record

ArticleCancers2025

Sequential Treatment with Regorafenib and Trifluridine/Tipiracil ± Bevacizumab in Refractory Metastatic Colorectal Cancer in Community Clinical Practice in the USA.

Daniel H Ahn, Tanios S Bekaii-Saab, Chengbo Yuan, Milena Kurtinecz, Xiaoyun Pan, Zdravko Vassilev, Federica Pisa, Helene Ostojic

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daniel H AhnMayo Clinic, Phoenix, AZ 85054, USA.
Tanios S Bekaii-SaabMayo Clinic, Phoenix, AZ 85054, USA.
Chengbo YuanReal World Evidence Oncology, Bayer HealthCare Pharmaceuticals, Whippany, NJ 07981, USA.ORCID 0000-0002-9004-0908
Milena KurtineczReal World Evidence Oncology, Bayer HealthCare Pharmaceuticals, Whippany, NJ 07981, USA.
Xiaoyun PanReal World Evidence Oncology, Bayer HealthCare Pharmaceuticals, Whippany, NJ 07981, USA.
Zdravko VassilevReal World Evidence Oncology, Bayer HealthCare Pharmaceuticals, Whippany, NJ 07981, USA.ORCID 0000-0002-4902-6784
Federica PisaBayer Consumer Care AG, 4052 Basel, Switzerland.ORCID 0000-0003-0459-2616
Helene OstojicReal World Evidence Oncology, Bayer AG, 13342 Berlin, Germany.ORCID 0000-0002-0448-9195

Funding

Bayer N/A
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

colorectal cancercommunity practicemetastaticreal worldrefractoryRegorafenibsequenceTAS-102Trifluridine/Tipiracil

Identifiers

PMID40149304
PMCPMC11939964

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.